PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 23, 2026Journal of Crohn s and Colitis

P0896Ten years’ experience with the treatment of checkpoint inhibitor-induced (entero)colitis: a Dutch two-centre approach

View Full Paper
Ask AI
Bookmark
Share

Authors

MNM NaberMEMick J M van EijsJHJ Huitema

Discussion

Loading...

Member takes

Overview

This retrospective analysis evaluates management of ICI colitis in patients, suggesting treatment patterns have evolved over time.

Key Points

  • This study aims to assess the characteristics and treatment trends of patients with checkpoint inhibitor-induced colitis.
  • Retrospective identification of patients with ICI colitis from 2014 to 2024.
  • Collected clinical characteristics and treatment data, stratifying cohorts by diagnosis date.
  • Performed univariate logistic regression to find associations with early SIT use.
  • 279 patients included; 125 diagnosed between 2022 and 2024.
  • SIT required by 40% of patients after first-line treatment.
  • Vedolizumab use as first SIT increased from 16% to 33% over time.
  • No change in frequency of SIT use between cohorts (37% vs 44%).
  • Early SIT initiation linked to higher hospitalization rates (OR 16.4).

Cite This Study

Naber et al. (2026) studied this question.

synapsesocial.com/papers/69730f78c8125b09b0d1f523https://doi.org/10.1093/ecco-jcc/jjaf231.1077
View Full Paper
Ask AI
Bookmark
Share